Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carter

Showing results (811-820 of 872) with videos related to

Pageof 88
Sort By:
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 1998
Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study GroupJ H Carter, B J Stewart, P G Archbold, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
Nature Communications|February 6, 2021
Control of zeolite microenvironment for propene synthesis from methanolLongfei Lin, Mengtian Fan, Alena M Sheveleva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Medchemcomm|August 16, 2018
Identification of imidazo[1,2-<i>b</i>]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signallingR Moslin, D Gardner, J Santella, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Pageof 88

Showing results (811-820 of 872) with videos related to

Sort By:
Pageof 88
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 1998
Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study GroupJ H Carter, B J Stewart, P G Archbold, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxisJoseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
Nature Communications|February 6, 2021
Control of zeolite microenvironment for propene synthesis from methanolLongfei Lin, Mengtian Fan, Alena M Sheveleva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Medchemcomm|August 16, 2018
Identification of imidazo[1,2-<i>b</i>]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signallingR Moslin, D Gardner, J Santella, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Pageof 88